Skip to main content

Table 4 Subgroup analysis between the low-dose CNI group and the standard-dose CNI group

From: Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis

Outcomes Low-dose CNI Standard-dose CNI Subgroup differences
Number of trials Number of patients RR/WMD 95% CI Number of trials Number of patients RR/WMD 95% CI p value Heterogeneity p value (%)
1-year AR rate 2 135 0.57 0.27, 1.17 2 62 3 0.51, 17.82 0.09 65.4
1-year graft survival rate 1 103 0.98 0.92, 1.05 2 62 1 0.9, 1.11 0.77 0
DGF rate 1 103 0.98 0.26, 3.71 1 42 0.29 0.07, 1.22 0.22 33.7
1-year infection rate 2 135 0.6 0.4, 0.88 2 62 0.82 0.41, 1.63 0.43 0
Renal graft function postsurgery at 12 months 2 135 −2.96 −11.12, 5.21 2 62 1.05 −7.88, 9.97 0.52 0
  1. MSCs mesenchymal stromal cells, AR acute rejection, DGF delay graft function, RR risk ratio, WMD weighted mean difference, CI confidence intervals